Nom du produit:ethyl 6-methyl-5-nitropyridine-3-carboxylate
IUPAC Name:ethyl 6-methyl-5-nitropyridine-3-carboxylate
- CAS：1211538-09-8
- Formule moléculaire：C9H10N2O4
- Pureté：98%
- Numéro de catalogue：CM106048
- Poids moléculaire：210.19
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1211538-09-8
- Formule moléculaire:C9H10N2O4
- Point de fusion:-
- Code SMILES:O=C(C1=CC([N+]([O-])=O)=C(C)N=C1)OCC
- Densité:
- Numéro de catalogue:CM106048
- Poids moléculaire:210.19
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Saruparib
- Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers, according to results from the phase I/II PETRA trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.
Saruparib, a PARP1-specific inhibitor, showed promising tumor growth inhibition in preclinical models of breast, ovarian, pancreatic, and prostate cancer harboring HRR deficiency mutations. Because saruparib was less toxic than other PARP inhibitors, it could be given at higher doses.
Recherche 
+86 21 5895 0110 
